Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/32IqIEO
via IFTTT